A Phase 2 interventional study of BI 1291583 and Placebo to BI 1291583 in Cystic Fibrosis and Bronchiectasis, sponsored by Boehringer Ingelheim. Completed at 24 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Cystic Fibrosis by Boehringer Ingelheim — none open to participants now, 1 under way, none of them phase 3. Cystic Fibrosis · Boehringer Ingelheim.
Among the 11 studies in Cystic Fibrosis by Boehringer Ingelheim, this one is the 9th largest by enrollment, is one of 2 that started in 2024, is one of 4 in phase 2, and was the 9th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →None of the 11 studies in Cystic Fibrosis by Boehringer Ingelheim is open now. The open studies under Cystic Fibrosis, anywhere →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 6 · Phase 3 1
First in 2001; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 52 across the 11 interventional studies. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Cystic Fibrosis by Boehringer Ingelheim, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is open to adults aged 18 years and older with cystic fibrosis bronchiectasis.
The purpose of this study is to find out whether a medicine called BI 1291583 is tolerated by people with cystic fibrosis bronchiectasis. Participants are put randomly into 2 groups. One group takes BI 1291583 tablets and the other group takes placebo tablets. Placebo tablets look like BI 1291583 tablets but do not contain any medicine. Participants in both groups take 1 tablet once a day for 12 weeks. Participants have twice the chance of being placed in the BI 1291583 group than in the placebo group.
Participants are in the study for about 6 months. During this time, they visit the study site 7 times. At the visits, the doctors check the health of the participants and note any health problems that could have been caused by BI 1291583.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
History of pulmonary exacerbations requiring antibiotic treatment. In the 12 months before Visit 1, patients must have had either:
Exclusion Criteria:
Further exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BI 1291583
Drug: Placebo to BI 1291583
Once daily oral administration of 5 milligram (mg) tablets of BI 1291583 for 12 weeks.
Also known as: Verducatib
Once daily oral administration of tablets of placebo matching BI 1291583 for 12 weeks.
Occurrence of Any Treatment Emergent Adverse Events
Occurrence of any treatment emergent adverse events is expressed as percentages of participants with treatment emergent adverse events. Percentages are rounded to one decimal place.
Time frame: From first dose of trial drug administration until last dose of trial drug administration plus 28 days of residual effect period, up to 16 weeks.
Relative Change From Baseline in NE Activity, in Sputum, at Week 8 After First Drug Administration
Relative change from baseline in neutrophil elastase (NE) activity, in sputum, at Week 8 after first drug administration is reported. Relative change from baseline at Week 8 in neutrophil elastase was calculated as below: Relative fluorescence unit (RFU) at Week 8-Relative fluorescence unit at baseline)\*100%/Relative fluorescence unit at baseline.
Time frame: Before the first drug administration (baseline: mean value of screening and Week 0 prior to the first treatment intake) and Week 8 after first study drug administration.
Area Under the Curve of BI 1291583 in Plasma Over a Uniform Dosing Interval Tau=6h After the First Dose (AUC0-6)
Area under the curve of BI 1291583 in plasma over a uniform dosing interval tau=6h after the first dose (AUC0-6) is reported.
Time frame: Before drug administration and 1 hour (h), 3.5h, 6h after administration of the first dose of BI 1291583 at Day 1.
Area Under the Curve of BI 1291583 in Plasma Over a Uniform Dosing Interval Tau=6h at Steady State (AUC0-6,ss)
Area under the curve of BI 1291583 in plasma over a uniform dosing interval tau=6h at steady state (AUC0-6,ss) is reported.
Time frame: Before drug administration at Day 85 and 1 hour (h), 3.5h, 6h after administration of BI 1291583 at Day 85.
Maximum Measured Concentration of BI 1291583 in Plasma After the First Dose
Maximum measured concentration of BI 1291583 in plasma after the first dose is reported.
Time frame: Before drug administration and 1 hour (h), 3.5h, 6h, and 8h after administration of the first dose of BI 1291583 at Day 1.
Maximum Measured Concentration of BI 1291583 in Plasma at Steady State
Maximum measured concentration of BI 1291583 in plasma at steady state is reported.
Time frame: Before drug administration at Day 85 and 1 hour (h), 3.5h, 6h after administration of BI 1291583 at Day 85.
This was a randomised, double-blind, placebo-controlled, parallel group trial evaluating safety, tolerability, pharmacodynamics and pharmacokinetics of BI 1291583 one tablet once daily over 12 weeks versus placebo in adult patients with cystic fibrosis bronchiectasis (Clairafly™).
| Milestone | Placebo | 5 mg BI 1291583 |
|---|---|---|
| Started | 7 | 15 |
| Completed | 7 | 14 |
| Not completed | 0 | 1 |
| Withdrew: Serious adverse event | 0 | 1 |
Occurrence of any treatment emergent adverse events is expressed as percentages of participants with treatment emergent adverse events. Percentages are rounded to one decimal place.
| Percentage of participants | Placebo | BI 1291583 5 mg |
|---|---|---|
| Occurrence of Any Treatment Emergent Adverse Events | 85.7 | 93.3 |
Relative change from baseline in neutrophil elastase (NE) activity, in sputum, at Week 8 after first drug administration is reported. Relative change from baseline at Week 8 in neutrophil elastase was calculated as below: Relative fluorescence unit (RFU) at Week 8-Relative fluorescence unit at baseline)\*100%/Relative fluorescence unit at baseline.
| percent change in RFU | Placebo | 5 mg BI 1291583 |
|---|---|---|
| Relative Change From Baseline in NE Activity, in Sputum, at Week 8 After First Drug Administration | 39.69 ± 134.67 | -65.95 ± 49.37 |
Area under the curve of BI 1291583 in plasma over a uniform dosing interval tau=6h after the first dose (AUC0-6) is reported.
| hours *nanomole/Liter (h*nmol/L) | 5 mg BI 1291583 |
|---|---|
| Area Under the Curve of BI 1291583 in Plasma Over a Uniform Dosing Interval Tau=6h After the First Dose (AUC0-6) | 14.0 ± 65.3 |
Area under the curve of BI 1291583 in plasma over a uniform dosing interval tau=6h at steady state (AUC0-6,ss) is reported.
| hours *nanomole/Liter (h*nmol/L) | 5 mg BI 1291583 |
|---|---|
| Area Under the Curve of BI 1291583 in Plasma Over a Uniform Dosing Interval Tau=6h at Steady State (AUC0-6,ss) | 65.9 ± 64.5 |
Maximum measured concentration of BI 1291583 in plasma after the first dose is reported.
| nmol/L | 5 mg BI 1291583 |
|---|---|
| Maximum Measured Concentration of BI 1291583 in Plasma After the First Dose | 3.33 ± 74.4 |
Maximum measured concentration of BI 1291583 in plasma at steady state is reported.
| nmol/L | 5 mg BI 1291583 |
|---|---|
| Maximum Measured Concentration of BI 1291583 in Plasma at Steady State | 11.6 ± 69.9 |
Collected over All-Cause Mortality, Serious Adverse Events and other adverse events: From first dose of trial drug administration until last dose of trial drug administration plus 28 days of residual effect period, up to 16 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/7 (0%) | 1/7 (14.3%) | 6/7 (85.7%) |
| 5 mg BI 1291583 | 0/15 (0%) | 5/15 (33.3%) | 13/15 (86.7%) |
| Event | Placebo | 5 mg BI 1291583 |
|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 0/7 | 3/15 |
| Infective exacerbation of bronchiectasisInfections and infestations | 1/7 | 1/15 |
| Hepatic cirrhosisHepatobiliary disorders | 0/7 | 1/15 |
| SeizureNervous system disorders | 0/7 | 1/15 |
| Event | Placebo | 5 mg BI 1291583 |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 2/7 | 0/15 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 2/7 | 0/15 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 1/7 | 4/15 |
| AnaemiaBlood and lymphatic system disorders | 1/7 | 0/15 |
| Conjunctivitis allergicEye disorders | 1/7 | 0/15 |
| EnteritisGastrointestinal disorders | 1/7 | 0/15 |
| Otitis externaInfections and infestations | 1/7 | 0/15 |
| PneumoniaInfections and infestations | 1/7 | 0/15 |
| Pneumonia viralInfections and infestations | 1/7 | 0/15 |
| HeadacheNervous system disorders | 1/7 | 2/15 |
Treated Set (TS): included all randomised patients who were documented to have taken at least one dose of investigational treatment.
| Age, Continuous(years) | Placebo | 5 mg BI 1291583 | Total |
|---|---|---|---|
| Mean | 32.4 ± 9.4 | 32.3 ± 11.0 | 32.4 ± 10.3 |
| Sex: Female, Male(Participants) | Placebo | 5 mg BI 1291583 | Total |
|---|---|---|---|
| Female | 4 | 5 | 9 |
| Male | 3 | 10 | 13 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 5 mg BI 1291583 | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 7 | 14 | 21 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | 5 mg BI 1291583 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 7 | 15 | 22 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing
Ran from Apr 2024 to primary completion in Oct 2024, 6 months.
Results were first posted in Nov 2025, 1 year 1 month after primary completion.
Of 40 industry-sponsored phase 2 interventional studies under Cystic Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 6 months is below that.
Counting every sponsor, half of 57 studies reached it within 21 months; a quarter within 9 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Verducatib